Literature DB >> 11395153

Is paradoxical pharmacology a strategy worth pursuing?

R A Bond1.   

Abstract

The first rule of medicine is, 'do no harm'. Perhaps accepting this precept has produced a logic for disease treatment where our primary purpose is limited to only assisting or helping to correct a malfunctioning system. Can we use drugs that, according to traditional views, would be considered to increase stress on the system in the short term, to actually treat and cure disease in the long term? Is it possible to exacerbate disease for a longer-term gain? Although there are several examples of where this strategy has appeared to work, a systematic testing of the hypothesis has not occurred and, for the majority of diseases, this hypothesis has never been tested.

Mesh:

Substances:

Year:  2001        PMID: 11395153     DOI: 10.1016/s0165-6147(00)01711-9

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  21 in total

1.  Plausibility and evidence: the case of homeopathy.

Authors:  Lex Rutten; Robert T Mathie; Peter Fisher; Maria Goossens; Michel van Wassenhoven
Journal:  Med Health Care Philos       Date:  2013-08

2.  The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

Authors:  Nicola A Hanania; Supria Singh; Rami El-Wali; Michael Flashner; Amie E Franklin; William J Garner; Burton F Dickey; Sergio Parra; Stephen Ruoss; Felix Shardonofsky; Brian J O'Connor; Clive Page; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2007-07-17       Impact factor: 3.410

3.  Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.

Authors:  Rui Lin; Simone Degan; Barbara S Theriot; Bernard M Fischer; Ryan T Strachan; Jiurong Liang; Richard A Pierce; Mary E Sunday; Paul W Noble; Monica Kraft; Arnold R Brody; Julia K L Walker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 4.  beta-Adrenoceptor inverse agonists in asthma.

Authors:  Burton F Dickey; Julia K L Walker; Nicola A Hanania; Richard A Bond
Journal:  Curr Opin Pharmacol       Date:  2010-06       Impact factor: 5.547

Review 5.  For the love of paradox: from neurobiology to pharmacology.

Authors:  Richard A Bond; Heather Giles
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

6.  Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.

Authors:  Long P Nguyen; Rui Lin; Sergio Parra; Ozozoma Omoluabi; Nicola A Hanania; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  GPCRs and arrestins in airways: implications for asthma.

Authors:  Raymond B Penn; Richard A Bond; Julia K L Walker
Journal:  Handb Exp Pharmacol       Date:  2014

9.  β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model.

Authors:  Vaidehi J Thanawala; Gloria S Forkuo; Nour Al-Sawalha; Zoulikha Azzegagh; Long P Nguyen; Jason L Eriksen; Michael J Tuvim; Thomas W Lowder; Burton F Dickey; Brian J Knoll; Julia K L Walker; Richard A Bond
Journal:  Am J Respir Cell Mol Biol       Date:  2012-11-29       Impact factor: 6.914

10.  Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model.

Authors:  Long P Nguyen; Ozozoma Omoluabi; Sergio Parra; Joanna M Frieske; Cecilia Clement; Zoulikha Ammar-Aouchiche; Samuel B Ho; Camille Ehre; Mehmet Kesimer; Brian J Knoll; Michael J Tuvim; Burton F Dickey; Richard A Bond
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-20       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.